May 5th, 2026

The call conveys a generally positive commercial and strategic outlook: strong top-line product growth (26% YoY overall; 31% YoY for TAVALISSE and REZLIDHIA), clear 2026 guidance and a pathway to full-year profitability, alongside promising early clinical data for R289 and expanded international partner revenues. Offsetting risks include rising operating expenses, a modest decline in quarterly net income and cash, seasonal Q1 reimbursement headwinds, a slower-growing GAVRETO franchise, and the termination of the Lilly collaboration for the RIPK1 asset (creating program-level uncertainty). On balance, the highlights—robust product sales growth, maintained guidance, pipeline progress and improved financing flexibility—outweigh the lowlights.

Company Guidance

Management reiterated 2026 guidance for total revenues of $275–$290 million, comprising net product sales of $255–$265 million and contract revenues of $20–$25 million, and affirmed their expectation to deliver positive net income for the full year. In Q1 they reported total revenue of $58.8M (net product sales $54.9M, +26% YoY) including TAVALISSE $37.3M (+31%), GAVRETO $9.6M (+7%) and REZLIDHIA $8.0M (+31%), plus $3.9M collaboration revenue; net product sales were recorded net of $20.5M of discounts/allowances. Q1 cost of product sales was ~$4.6M, total costs and expenses were $46.9M (vs. $40.6M prior year), income before taxes $11.7M and net income $8.7M (vs. $11.4M). Balance sheet and financing items noted: cash, cash equivalents and short‑term investments of $146.7M (down from $155.0M at 12/31/25), repayment of a $40M term loan and establishment of a $40M revolving credit facility (option to increase to $60M) with $8M drawn; guidance excludes any assumed revenues from the Lilly collaboration.